Company intelligence / Profile preview
Allterum Therapeutics
Houston, Texas, United Statesallterum.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Allterum is developing 4A10, an anti-CD127 monoclonal antibody for treating acute lymphoblastic leukemia and other CD127-expressing cancers. The company is preparing to launch Phase I/II clinical trials. Pre-clinical studies have shown promise for the treatment of CD127-expressing cancers.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Baylor College of MedicineTexas Children's HospitalChildren's Oncology Group (COG)National Cancer Institute (NCI)Leukemia and Lymphoma SocietyUniversity of Texas MD Anderson Cancer CenterFUJIFILM Diosynth BiotechnologiesThe Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)
Beyond the preview
Go deeper on Allterum Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allterum Therapeutics.